Ginkgo Bioworks is a synthetic biology engineering platform helping companies create sustainable biological products, though it currently trades with a massive cash deficit and shrinking revenue base.
Bullish investors see Ginkgo as a deep-tech leader with an entrenched biofoundry platform that could eventually monetize at scale once market conditions stabilize and partnerships mature. The narrowing net loss indicates the company is finding a path to operational sustainability, potentially unlocking value for early stakeholders if revenue growth resumes.
Bearish analysts point to the unsustainable financial trajectory where revenue dropped 64% from 2022 to 2025 while accumulating a massive deficit in retained earnings. Without a clear catalyst to reverse the revenue slide and stop cash burn, the company risks dilution or insolvency given its heavy reliance on external financing.
Ginkgo Bioworks (DNA) is a synthetic biology platform enabling customers to design and manufacture biological solutions for agriculture, medicine, and consumer goods. The company operates through its proprietary 'Biofoundry' network, providing engineering services and manufacturing capabilities across the United States and internationally. Recent financials reflect a strategic pivot toward profitability with revenue declining from $477.7M in 2022 to $170.2M in 2025 while net losses narrowed significantly.
Management successfully narrowed the net loss from $-547.0M in 2024 to $-312.8M in 2025, demonstrating improved operational efficiency and cost control measures. However, this improvement comes alongside a steep revenue decline to $170.2M, raising concerns that the company may be shrinking its business to survive rather than scaling growth. The massive cash outflow for investing activities suggests significant asset restructuring or write-downs impacting the balance sheet.
The synthetic biology industry is rapidly evolving with applications in sustainable agriculture, carbon capture, and bio-manufacturing, yet it remains capital intensive with long development cycles. Companies must balance high upfront R&D investments against the need to generate recurring service revenue to achieve profitability in a crowded market.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $477.7M | $251.5M | $227.0M | $170.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $477.7M | $251.5M | $227.0M | $170.2M |
| Operating Expenses | $2.69B | $1.12B | $786.8M | $485.4M |
| Operating Income | $-2.21B | $-864.4M | $-559.8M | $-315.3M |
| R&D | $1.05B | $580.6M | $424.1M | $243.8M |
| G&A | $1.43B | $385.0M | $246.2M | $183.3M |
| Stock-Based Comp | $1.93B | $229.9M | $112.3M | $81.5M |
| D&A | $42.6M | $70.5M | $63.0M | $59.0M |
| Depreciation | $36.9M | $54.8M | $45.0M | $40.3M |
| Amortization | $5.6M | $15.7M | $18.0M | $18.7M |
| Other OpEx | $204.2M | $150.2M | $116.6M | $58.4M |
| Non-Operating Income | $87.6M | $-28.5M | $12.2M | $1.7M |
| Interest Expense | $106.0K | $93.0K | — | — |
| Interest Income | $20.3M | $57.2M | $38.6M | $22.6M |
| Pre-Tax Income | $-2.12B | $-892.9M | $-547.5M | $-313.6M |
| Income Tax | $-15.0M | $-71.0K | $-479.0K | $-837.0K |
| Continuing Ops | $-2.11B | $-892.9M | $-547.0M | $-312.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-2.11B | $-892.9M | $-547.0M | $-312.8M |
| Minority Interest | $-1.4M | $0 | $0 | $0 |
| Net to Common | $-2.10B | $-892.9M | $-547.0M | $-312.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.45B | $1.00B | $602.7M | $471.8M |
| Cash & Equivalents | $1.32B | $944.1M | $561.6M | $167.2M |
| Marketable Securities | — | — | — | $255.4M |
| Accounts Receivable | $80.9M | $17.2M | $21.9M | $24.0M |
| Inventory | $4.4M | $46.0K | — | — |
| Prepaid Expenses | $47.5M | $39.8M | $18.7M | $25.0M |
| Other Current Assets | $1.6M | $696.0K | $586.0K | $229.0K |
| Long-Term Assets | $1.09B | $663.6M | $774.7M | $647.9M |
| PP&E (Net) | $314.8M | $188.2M | $203.7M | $167.8M |
| Intangibles | $111.0M | $82.7M | $72.5M | $56.9M |
| Goodwill | $60.2M | $49.2M | $0 | — |
| Operating Leases | $400.8M | $206.8M | $394.4M | $360.9M |
| Other LT Assets | $200.9M | $136.6M | $104.0M | $62.2M |
| Total Assets | $2.54B | $1.67B | $1.38B | $1.12B |
| Current Liabilities | $173.0M | $163.9M | $107.3M | $96.0M |
| Accounts Payable | $10.5M | $9.3M | $14.2M | $10.6M |
| Current Leases | $28.0M | $18.9M | $28.6M | $22.8M |
| Deferred Revenue | — | $44.5M | $27.7M | $18.9M |
| Other Current Liab | $19.8M | $91.2M | $36.8M | $43.7M |
| Long-Term Liabilities | $630.1M | $404.3M | $554.1M | $515.1M |
| LT Operating Leases | $413.3M | $221.8M | $438.8M | $417.1M |
| Other LT Liab | $216.8M | $24.4M | $16.6M | $22.9M |
| Total Liabilities | $803.0M | $568.2M | $661.4M | $611.1M |
| Shareholders' Equity | $1.74B | $1.10B | $716.1M | $508.6M |
| Paid-In Capital | $6.14B | $6.39B | $6.56B | $6.66B |
| Retained Earnings | $-4.40B | $-5.29B | $-5.84B | $-6.15B |
| AOCI | $-2.6M | $1.5M | $-1.8M | $1.9M |
| Total L&E | $2.54B | $1.67B | $1.38B | $1.12B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-2.11B | $-892.9M | $-547.0M | $-312.8M |
| Non-Cash Adjustments | $1.98B | $703.0M | $348.5M | $176.8M |
| Working Capital Changes | $-123.5M | $-105.7M | $-121.1M | $-35.1M |
| Cash from Operations | $-252.2M | $-295.5M | $-319.6M | $-171.1M |
| Capital Expenditures | $52.3M | $40.8M | $62.5M | $7.7M |
| Cash from Investing | $-67.4M | $-80.7M | $-62.2M | $-240.3M |
| Cash from Financing | $95.3M | $-3.2M | $-1.7M | $17.8M |
| FX Effect | $908.0K | $-588.0K | $-281.0K | $201.0K |
| Net Change in Cash | $-223.3M | $-380.0M | $-383.8M | $-393.4M |
| Beginning Cash | $1.59B | $1.37B | $989.6M | $605.7M |
| Ending Cash | $1.37B | $989.6M | $605.7M | $212.4M |
The company's revenue is primarily derived from contract manufacturing services where customers pay to produce their engineered microbes, alongside engineering fees for designing new biological pathways. A significant portion of operating expenses relates to high R&D costs ($243.8M) and share-based compensation ($81.5M), indicating a service-heavy model reliant on external partnerships rather than proprietary product sales.
The company faces severe liquidity risks with $1.12B in total assets offset by $611.1M in liabilities and a retained earnings deficit of $-6.15B, requiring continued capital raises or dilution. Revenue has contracted sharply over the last three years, suggesting intense competition or a loss of key customers that threatens long-term viability. High cash burn from operations ($-171.1M) and investing activities ($-240.3M) depletes cash reserves despite interest income.
Ginkgo possesses a unique 'Biofoundry' infrastructure that accelerates the design-build-test cycle for synthetic biology projects, offering speed that traditional biotech firms lack. The company leverages its extensive library of engineered microbes and automated manufacturing facilities to offer a scalable platform rather than competing directly on specific commodity products.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.